Joel L Ramirez1, Warren J Gasper2, Sukaynah A Khetani2, Greg J Zahner1, Nancy K Hills3, Pete T Mitchell4, Brian E Sansbury4, Michael S Conte1, Matthew Spite4, S Marlene Grenon5. 1. Division of Vascular and Endovascular Surgery, Department of Surgery, University of California, San Francisco, California. 2. Division of Vascular and Endovascular Surgery, Department of Surgery, University of California, San Francisco, California; Vascular Surgery Section, Veterans Affairs Medical Center, San Francisco, California. 3. Department of Epidemiology and Biostatistics, University of California, San Francisco, California. 4. Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Building for Transformative Medicine, Boston, Massachusetts. 5. Division of Vascular and Endovascular Surgery, Department of Surgery, University of California, San Francisco, California. Electronic address: marlene.grenon@ucsf.edu.
Abstract
BACKGROUND:N-3polyunsaturated fatty acid (PUFA) supplementation has been associated with reduced mortality and inflammation in patients with cardiovascular disease. There are limited data on the effects of n-3 PUFA supplementation in patients with peripheral artery disease (PAD). MATERIALS AND METHODS: The OMEGA-PAD II trial was a double-blinded, randomized, placebo-controlled trial to assess the effect of 3 mo of high-dose oral n-3 PUFA supplementation on inflammation, endothelial function, and walking ability in patients with PAD. RESULTS: Twenty-four patients with claudication received 4.4 g/d of fish oil or placebo for 3 mo. Outcomes measured included high-sensitivity C-reactive protein levels, the omega-3 index, endothelial function as measured via flow-mediated vasodilation, walking impairment questionnaire, and a 6-min walk test. Plasma levels of specialized pro-resolving lipid mediators (SPMs) were measured by liquid-chromatography-tandem mass spectrometry. In patients treated with fish oil, the absolute mean omega-3 index significantly increased from baseline (fish oil: 7.2 ± 1.2%, P < 0.001; placebo: -0.4 ± 0.9%, P = 0.31; between-group P < 0.001). Furthermore, there were significant increases in several pathway markers of SPM biosynthesis, including several mono-hydroxyeicosapentaenoic acids and mono-hydroxydocosahexaenoic acids. We also observed significant increases in the SPM lipoxin A5 (fish oil: 0.57 ± 0.70 pg/mL, P = 0.05; placebo: 0.01 ± 0.38 pg/mL, P = 0.93; between-group P = 0.04) and resolvin E3 (fish oil: 154 ± 171 pg/mL, P = 0.04; placebo: 32 ± 54 pg/mL, P = 0.08; between-group P = 0.04). There were no significant changes in high-sensitivity C-reactive protein, flow-mediated vasodilation, walking impairment questionnaire, or 6-min walk test in the fish oil group. CONCLUSIONS:Fish oil increases SPMs in plasma of patients with PAD. Further studies are required to determine whether these early changes translate to clinical improvements in patients with PAD.
RCT Entities:
BACKGROUND:N-3 polyunsaturated fatty acid (PUFA) supplementation has been associated with reduced mortality and inflammation in patients with cardiovascular disease. There are limited data on the effects of n-3 PUFA supplementation in patients with peripheral artery disease (PAD). MATERIALS AND METHODS: The OMEGA-PAD II trial was a double-blinded, randomized, placebo-controlled trial to assess the effect of 3 mo of high-dose oral n-3 PUFA supplementation on inflammation, endothelial function, and walking ability in patients with PAD. RESULTS: Twenty-four patients with claudication received 4.4 g/d of fish oil or placebo for 3 mo. Outcomes measured included high-sensitivity C-reactive protein levels, the omega-3 index, endothelial function as measured via flow-mediated vasodilation, walking impairment questionnaire, and a 6-min walk test. Plasma levels of specialized pro-resolving lipid mediators (SPMs) were measured by liquid-chromatography-tandem mass spectrometry. In patients treated with fish oil, the absolute mean omega-3 index significantly increased from baseline (fish oil: 7.2 ± 1.2%, P < 0.001; placebo: -0.4 ± 0.9%, P = 0.31; between-group P < 0.001). Furthermore, there were significant increases in several pathway markers of SPM biosynthesis, including several mono-hydroxyeicosapentaenoic acids and mono-hydroxydocosahexaenoic acids. We also observed significant increases in the SPM lipoxin A5 (fish oil: 0.57 ± 0.70 pg/mL, P = 0.05; placebo: 0.01 ± 0.38 pg/mL, P = 0.93; between-group P = 0.04) and resolvin E3 (fish oil: 154 ± 171 pg/mL, P = 0.04; placebo: 32 ± 54 pg/mL, P = 0.08; between-group P = 0.04). There were no significant changes in high-sensitivity C-reactive protein, flow-mediated vasodilation, walking impairment questionnaire, or 6-min walk test in the fish oil group. CONCLUSIONS:Fish oil increases SPMs in plasma of patients with PAD. Further studies are required to determine whether these early changes translate to clinical improvements in patients with PAD.
Authors: Vany Nascimento-Silva; Maria Augusta Arruda; Christina Barja-Fidalgo; Iolanda M Fierro Journal: Thromb Haemost Date: 2007-01 Impact factor: 5.249
Authors: Deepak L Bhatt; P Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Christie M Ballantyne Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Karen J Ho; Matthew Spite; Christopher D Owens; Hope Lancero; Alex H K Kroemer; Reena Pande; Mark A Creager; Charles N Serhan; Michael S Conte Journal: Am J Pathol Date: 2010-08-13 Impact factor: 4.307
Authors: Christopher D Owens; Paul M Ridker; Michael Belkin; Allen D Hamdan; Frank Pomposelli; Frank Logerfo; Mark A Creager; Michael S Conte Journal: J Vasc Surg Date: 2006-11-21 Impact factor: 4.268
Authors: William S Harris; James V Pottala; Stephen A Varvel; James J Borowski; Jennie N Ward; Joseph P McConnell Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2013-01-31 Impact factor: 4.006
Authors: Tarec K Elajami; Romain A Colas; Jesmond Dalli; Nan Chiang; Charles N Serhan; Francine K Welty Journal: FASEB J Date: 2016-04-27 Impact factor: 5.191
Authors: David R Morgan; Lana J Dixon; Colm G Hanratty; Naglaa El-Sherbeeny; Paul B Hamilton; Lawrence T McGrath; William J Leahey; G Dennis Johnston; Gary E McVeigh Journal: Am J Cardiol Date: 2006-01-04 Impact factor: 2.778
Authors: Stephania Libreros; Ashley E Shay; Robert Nshimiyimana; David Fichtner; Michael J Martin; Nicholas Wourms; Charles N Serhan Journal: Front Immunol Date: 2021-02-10 Impact factor: 7.561
Authors: Jill Hahn; Nancy R Cook; Erik K Alexander; Sonia Friedman; Joseph Walter; Vadim Bubes; Gregory Kotler; I-Min Lee; JoAnn E Manson; Karen H Costenbader Journal: BMJ Date: 2022-01-26
Authors: Simon C Dyall; Laurence Balas; Nicolas G Bazan; J Thomas Brenna; Nan Chiang; Felipe da Costa Souza; Jesmond Dalli; Thierry Durand; Jean-Marie Galano; Pamela J Lein; Charles N Serhan; Ameer Y Taha Journal: Prog Lipid Res Date: 2022-05-01 Impact factor: 14.673